Étiquette : psychedelics

LSD enhances suggestibility in healthy volunteers, R. L. Carhart-Harris et al., 2014

LSD enhances suggestibility in healthy volunteers R. L. Carhart-Harris, M. Kaelen, M. G. Whalley, M. Bolstridge, A. Feilding, D. J. Nutt Psychopharmacology, 2014 DOI 10.1007/s00213-014-3714-z   Abstract Rationale : Lysergic acid diethylamide (LSD) has a history of use as a psychotherapeutic aid in the treatment of mood disorders and addiction, and it was also explored as an enhancer of mind control. Objectives : The present study sought to test the effect of LSD on suggestibility in a modern research study. Methods : Ten healthy volunteers were administered with intravenous (i.v.) LSD (40–80 μg) in a within-subject placebocontrolled design. Suggestibility and cued mental imagery were assessed using the Creative [...]

Lire la suite

The psychedelic renaissance : the next trip for psychiatry ?, J. R. Kelly et al., 2019

The psychedelic renaissance : the next trip for psychiatry ? J. R. Kelly, A. Baker, M. Babiker, L. Burke, C. Brennan and V. O’Keane Irish Journal of Psychological Medicine, 2019, 1 - 5 doi : 10.1017/ipm.2019.39   Abstract The psychedelic research renaissance is gaining traction. Preliminary clinical studies of the hallucinogenic fungi, psilocybin, with psychological support, have indicated improvements in mood, anxiety and quality of life. A seminal, open-label study demonstrated marked reductions in depression symptoms in participants with treatment-resistant depression (TRD). The associated neurobiological processes involve alterations in brain connectivity, together with altered amygdala and default mode network activity. At the cellular level, psychedelics promote [...]

Lire la suite

Serotonergic hallucinogens/psychedelics could be promising treatments for depressive and anxiety disorders in endstage cancer, Rafael Guimarães dos Santos et al., 2019

Serotonergic hallucinogens/psychedelics could be promising treatments for depressive and anxiety disorders in endstage cancer Rafael Guimarães dos Santos, José Carlos Bouso and Jaime E. C. Hallak BMC Psychiatry, 2019, 19, 321 https://doi.org/10.1186/s12888-019-2288-z   Abstract In a recent issue of the BMC Psychiatry, the evidence of effectiveness of treatments for psychiatric conditions in end-stage cancer patients was reviewed (Johnson, 2018). The review was comprehensive, and included traditional and non-traditional/alternative treatments, including herbal medicines and spirituality. However, evidence showing that classic or serotonergic hallucinogens/psychedelics such as psilocybin and lysergic acid diethylamide (LSD) could be effective treatments for depressive and anxiety disorders in end-stage cancer was not included. In [...]

Lire la suite

Antidepressive and anxiolytic effects of ayahuasca : a systematic literature review of animal and human studies, Rafael G. dos Santos et al., 2016

Antidepressive and anxiolytic effects of ayahuasca : a systematic literature review of animal and human studies Rafael G. dos Santos, Flavia L. Osorio, José Alexandre S. Crippa, Jaime E.C. Hallak Revista Brasileira de Psiquiatria, 2016, 38, 65–72 doi:10.1590/1516-4446-2015-1701   ABSTRACT Objective : To conduct a systematic literature review of animal and human studies reporting anxiolytic or antidepressive effects of ayahuasca or some of its isolated alkaloids (dimethyltryptamine, harmine, tetrahydroharmine, and harmaline). Methods : Papers published until 3 April 2015 were retrieved from the PubMed, LILACS and SciELO databases following a comprehensive search strategy and using a predetermined set of criteria for article selection. Results : Five hundred and [...]

Lire la suite

The Impact of Ayahuasca on Suicidality : Results From a Randomized Controlled Trial, Richard J. Zeifman et al., 2019

The Impact of Ayahuasca on Suicidality : Results From a Randomized Controlled Trial Richard J. Zeifman, Fernanda Palhano-Fontes, Jaime Hallak, Emerson Arcoverde, João Paulo Maia-Oliveira, Draulio B. Araujo Frontiers in Pharmacology, 2019, Volume 10, Article 1325, 1-10. doi : 10.3389/fphar.2019.01325   Suicide is a major public health problem. Given increasing suicide rates and limitations surrounding current interventions, there is an urgent need for innovative interventions for suicidality. Although ayahuasca has been shown to target mental health concerns associated with suicidality (i.e., depression and hopelessness), research has not yet explored the impact of ayahuasca on suicidality. Therefore, we conducted secondary analyses of a randomized placebo-controlled trial in [...]

Lire la suite

Psilocybin-assisted therapy for depression : How do we advance the field ?, Sally E Meikle et al., 2019

Psilocybin-assisted therapy for depression : How do we advance the field ? Sally E Meikle, Paul Liknaitzky, Susan L Rossell, Margaret Ross, Nigel Strauss, Neil Thomas, Greg Murray, Martin Williams, David J Castle Australian & New Zealand Journal of Psychiatry, 2019, 1–7 Doi : 10.1177/0004867419888575   Abstract In the quest for new treatment options for depression, attention is being paid to the potential role of psychedelic drugs. Psilocybin is of particular interest given its mechanism of action, its benefits in early trials and its relatively low side effects burden. This viewpoint outlines a number of key issues that remain to be elucidated about its potential use [...]

Lire la suite

Psychedelics and music : neuroscience and therapeutic implications, Frederick S. Barrett et al., 2018

Psychedelics and music : neuroscience and therapeutic implications Frederick S. Barrett, Katrin H. Preller & Mendel Kaelen International Review of Psychiatry, 2018 https://doi.org/10.1080/09540261.2018.1484342   ABSTRACT From the beginning of therapeutic research with psychedelics, music listening has been consistently used as a method to guide or support therapeutic experiences during the acute effects of psychedelic drugs. Recent findings point to the potential of music to support meaning-making, emotionality, and mental imagery after the administration of psychedelics, and suggest that music plays an important role in facilitating positive clinical outcomes of psychedelic therapy. This review explores the history of, contemporary research on, and future directions regarding the use [...]

Lire la suite

Psychedelics : Where we are now, why we got here, what we must do, Sean J. Belouin & Jack E. Henningfield, 2018

Psychedelics : Where we are now, why we got here, what we must do Sean J. Belouin, Jack E. Henningfield Neuropharmacology, 2018, 142, 7e19 https://doi.org/10.1016/j.neuropharm.2018.02.018 a b s t r a c t The purpose of this commentary is to provide an introduction to this special issue of Neuropharmacology with a historical perspective of psychedelic drug research, their use in psychiatric disorders, research restricting regulatory controls, and their recent emergence as potential breakthrough therapies for several brain-related disorders. It begins with the discovery of lysergic acid diethylamide (LSD) and its promising development as a treatment for several types of mental illnesses during the 1940s. This was [...]

Lire la suite

Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression, Leor Roseman et al., 2018

Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression Leor Roseman, Lysia Demetriou, Matthew B. Wall, David J. Nutt, Robin L. Carhart-Harris Neuropharmacology, 2018, 142, 263e269. https://doi.org/10.1016/j.neuropharm.2017.12.041   Abstract Recent evidence indicates that psilocybin with psychological support may be effective for treating depression. Some studies have found that patients with depression show heightened amygdala responses to fearful faces and there is reliable evidence that treatment with SSRIs attenuates amygdala responses (Ma, 2015). We hypothesised that amygdala responses to emotional faces would be altered post treatment with psilocybin. In this open-label study, 20 individuals diagnosed with moderate to severe, treatment-resistant depression, underwent two separate dosing [...]

Lire la suite

Psychiatry & the psychedelic drugs. Past, present & future, James J.H. Rucker et al., 2018

Psychiatry & the psychedelic drugs. Past, present & future James J.H. Rucker, Jonathan Iliff, David J. Nutt Neuropharmacology, 2018, 142, 200e218 https://doi.org/10.1016/j.neuropharm.2017.12.040   a b s t r a c t The classical psychedelic drugs, including psilocybin, lysergic acid diethylamide and mescaline, were used extensively in psychiatry before they were placed in Schedule I of the UN Convention on Drugs in 1967. Experimentation and clinical trials undertaken prior to legal sanction suggest that they are not helpful for those with established psychotic disorders and should be avoided in those liable to develop them. However, those with so-called ‘psychoneurotic’ disorders sometimes benefited considerably from their tendency to [...]

Lire la suite